Overview Emmanuelle Trombe, Bertrand Delafaye and Mathilde Peschard advised a biotechnology company on its capital increase with cancellation of preferential subscription rights for EUR 8.65 million by accelerated construction of a book of orders. READ THE FULL ARTICLE
